NCT03543540 - Bioequivalence Study of Nexvax2 in Subjects With Celiac Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 1, 2018

Primary Completion Date

September 10, 2018

Study Completion Date

September 10, 2018

Conditions

Celiac DiseaseIntestinal DiseaseMalabsorption SyndromesGastrointestinal DiseaseDigestive System DiseasesMetabolic DiseaseCoeliac DiseaseGluten Sensitivity

Interventions

BIOLOGICAL

Nexvax2

Nexvax2 injections: 14 in total at twice weekly intervals

BIOLOGICAL

Placebo

Placebo injections: 14 in total at twice weekly intervals

Trial Locations (3)

4006

Qpharm Pty Ltd, Herston

4556

University of the Sunshine Coast, Sippy Downs

6009

Linear Clinical Research, Nedlands